There is a lot to digest tomorrow.
We are looking for evidence of efficacy (and safety) in the population with the required endpoints- the change in each child from initial measurements. The trial is designed so that it may potentially provide pivotal data (controlled, powered, right endpoints etc). Whilst these are the main points people will focus on i will be readily running my eyes over the text looking for the side effects. Safety has already been closely monitered and reviewed by an independent committee to approve each dose escalation and age group progression so i am confident the side effects may only be minimal at the highest dosing.
I do feel we will still progress to P3 even if we have a moderate result and for that fact i am not stressed about tomorrow.
- Forums
- ASX - By Stock
- NEU
- Ann: Trading Halt
Ann: Trading Halt, page-296
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.86 |
Change
0.560(2.90%) |
Mkt cap ! $2.538B |
Open | High | Low | Value | Volume |
$19.80 | $20.00 | $19.40 | $3.777M | 191.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1060 | $19.83 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.87 | 209 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1060 | 19.830 |
8 | 6809 | 19.790 |
1 | 2736 | 19.740 |
1 | 1108 | 19.710 |
3 | 1623 | 19.700 |
Price($) | Vol. | No. |
---|---|---|
19.890 | 708 | 2 |
19.900 | 1450 | 1 |
19.910 | 4224 | 3 |
19.920 | 915 | 1 |
19.950 | 434 | 1 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |